Palantir Technologies (PLTR), MicroStrategy (MSTR) and Axon Enterprise (AXON) will join the Nasdaq-100 next week, replacing Super Micro Computer (SMCI), Illumina (ILMN) and Moderna (MRNA).
Shares of the incoming trio are having mixed reactions to the announcement. MicroStrategy is in the lead, up 4% at last check, as inclusion in the Nasdaq-100 often boosts stocks due to demand from index-tracking funds, including the ever-popular Invesco QQQ Trust (QQQ). MicroStrategy stock is also benefiting from bitcoin's new record high of $106,000 over the weekend.
The rebalance of the Nasdaq-100 index will occur ahead of the market open on Monday, December 23.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
What Wall Street thinks about Palantir, MicroStrategy and Axon
Palantir, a tech company that specializes in big data analytics, has been one of the market's best-performing stocks in 2024 with a return of more than 340% in the year to date.
However, Wall Street thinks the tech stock has gotten ahead of itself as the consensus recommendation among the 20 covering analysts S&P Global Market Intelligence tracks is a Hold. Additionally, analysts' average target price for PLTR stock is $41.77, representing a discount of more than 40% to current levels.
But not everyone is on the sidelines when it comes to Palantir. Financial services firm Wedbush is one of the most bullish firms on PLTR with an Outperform rating (equivalent to a Buy) and a $75 price target.
"We are raising our price target on Palantir from $57 to $75, reflecting our increased confidence in the game-changing AIP strategy with use cases for artificial intelligence taking hold over the next 12-18 months," wrote Wedbush analyst Daniel Ives in a November 24 note. "The Messi of AI growth story will see unprecedented demand as more enterprises realize the value of PLTR's entire product suite with more AI use cases."
MicroStrategy, an enterprise software company that has become a bitcoin proxy due to its significant holdings in the cryptocurrency, has posted a jaw-dropping return of over 500% in the year to date.
Wall Street thinks the large-cap stock is going even higher from here with an average price target of $518.68, representing implied upside of about 24% to current levels. Additionally, the consensus recommendation is a Strong Buy.
Financial services firm Bernstein is the most bullish outfit on MSTR stock with an Outperforming rating (equivalent to a Buy) and a $2,890 price target.
"Since August 2020, MSTR has transformed from a small software company to the largest bitcoin holding company, owning 1.1% of world’s bitcoin supply worth roughly $14.5 billion," says Bernstein analyst Gautam Chhugani in a note this morning. "MSTR's founder chairman, Michael Saylor, has become synonymous with brand bitcoin and has positioned MSTR as a leading bitcoin company, attracting at-scale capital (both debt and equity) for an active bitcoin acquisition strategy."
Axon, a company that provides safety and security technology for law enforcement including tasers and body cameras, has risen more than 140% in the year to date, and Wall Street still rates it a Strong Buy. However, analysts' price targets have failed to keep up with the quick-rising growth stock as the average analyst estimate of $598.08 represents a discount of just over 3% to current levels.
Financial services firm Argus has a Buy rating and $800 price target on AXON stock.
"We expect AXON shares to continue to outpace the broader market, driven by the company's strong management team and robust earnings prospects as demand for its products and solutions remains strong," wrote Argus analyst John Staszak in a December 4 note. "We think that Axon can continue to generate positive earnings surprises based on its relatively cautious forecasts."
Related Content
-
15 Reasons You'll Regret an RV in RetirementMaking Your Money Last Here's why you might regret an RV in retirement. RV-savvy retirees talk about the downsides of spending retirement in a motorhome, travel trailer, fifth wheel or other recreational vehicle.
-
Medicare’s 2025 Drug Negotiation List Includes Weight-loss Drugs Ozempic and WegovyThe Centers for Medicare & Medicaid Services wants to lower the cost for 15 more drugs including Ozempic and Wegovy.
-
SLB Stock Jumps on Earnings, Dividend Hike and Buyback NewsSLB stock is soaring Friday after the energy firm reported strong fourth-quarter earnings and unveiled several shareholder-friendly initiatives.
-
Why J.B. Hunt Stock Is Sinking After EarningsJ.B. Hunt stock is notably lower Friday after the logistics company fell short of fourth-quarter earnings expectations. Here's what you need to know.
-
Converting Retirement Savings to a Roth IRA? Don't Do ThisYou might want to convert all of your savings to a Roth in one go, but you could end up paying hundreds of thousands more in taxes than you have to.
-
What Is Your 'Enough Is Enough' Number for Retirement?Chasing a 'magic number' for retirement can be anxiety-inducing. Instead, build your plans around a personal number that reflects your individual circumstances.
-
California Wildfires and Insurance: Looking for HelpLos Angeles-based insurance expert Karl Susman shares the view from his agency’s office as all hands are on deck to help their policyholders.
-
Stock Market Today: Stocks Pause After a Big RallyThe Nasdaq continues to lag the S&P 500 and the Dow so far in 2025.
-
Could ESG Funds be Removed from Your 401(k) Plan?A pilot successfully sued American Airlines for including ESG factors in its 401(k) plan.
-
UnitedHealth Is the Worst Dow Jones Stock Thursday. Here's WhyUnitedHealth is putting pressure on the 30-stock index Thursday after the insurance giant reported a rare revenue miss. This is what you need to know.
